Wang Xiumei, Liu Youde, Sun Jing, Gong Wenjing, Sun Ping, Kong Xiangshuo, Yang Miaomiao, Zhang Weiwei
1Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000 People's Republic of China.
2Department of Hepatology, Infectious Disease Hospital of Yantai City, Yantai, Shandong 264001 People's Republic of China.
Infect Agent Cancer. 2018 Nov 26;13:36. doi: 10.1186/s13027-018-0212-7. eCollection 2018.
To investigate the expression of Mitofusin-2 (MFN2) in HCC tissues and its role in the development of HCC.
A total of 107 HCC specimens were collected for tissue microarray analysis and immunohistochemistry (IHC) analysis. The relationship between MFN2 expression and clinical features of patients with HCC was analyzed.
Expression level of MFN2 in HCC tissues was 0.92 ± 0.78, significantly lower than that of matched paracancerous liver tissues (1.25 ± 0.75). Patients with low expression of MFN2 had significantly higher rates of cirrhosis than those with high expression of MFN2 ( = 0.049). Kaplan-Meier survival analysis showed that HCC patients with low expression of MFN2 had a worse prognosis in overall survival than HCC patients with high expression of MFN2 ( = 0.027). Patients with high expression of MFN2 had a better prognosis in disease-free survival compared with HCC patients with low expression of MFN2 ( = 0.047). Vascular invasion and MFN2 expression were shown to be prognostic variables for overall survival in patients with HCC. Multivariate analysis showed that vascular invasion ( < 0.001) and MFN2 expression ( = 0.045) were independent prognostic factors for overall survival. Vascular invasion ( < 0.001) and MFN2 expression ( = 0.042) were independent risk factors associated with disease-free survival.
Our data revealed that MFN2 expression was decreased in HCC samples. High MFN2 expression was correlated with longer survival times in patients with HCC and served as an independent factor for better outcomes. Our study therefore provides a promising biomarker for the prognostic prediction of HCC and a potential therapeutic target for the disease.
探讨线粒体融合蛋白2（MFN2）在肝癌组织中的表达及其在肝癌发生发展中的作用。
收集107例肝癌标本进行组织芯片分析和免疫组化（IHC）分析。分析MFN2表达与肝癌患者临床特征之间的关系。
肝癌组织中MFN2的表达水平为0.92±0.78，显著低于配对的癌旁肝组织（1.25±0.75）。MFN2低表达患者的肝硬化发生率显著高于MFN2高表达患者（P = 0.049）。Kaplan-Meier生存分析显示，MFN2低表达的肝癌患者总生存预后较MFN2高表达的肝癌患者差（P = 0.027）。与MFN2低表达的肝癌患者相比，MFN2高表达患者的无病生存预后更好（P = 0.047）。血管侵犯和MFN2表达是肝癌患者总生存的预后变量。多因素分析显示，血管侵犯（P < 0.001）和MFN2表达（P = 0.045）是总生存的独立预后因素。血管侵犯（P < 0.001）和MFN2表达（P = 0.042）是与无病生存相关的独立危险因素。
我们的数据显示肝癌样本中MFN2表达降低。MFN2高表达与肝癌患者较长的生存时间相关，是预后较好的独立因素。因此，我们的研究为肝癌的预后预测提供了一个有前景的生物标志物，并为该疾病提供了一个潜在的治疗靶点。
